ATE333888T1 - Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen - Google Patents
Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungenInfo
- Publication number
- ATE333888T1 ATE333888T1 AT01970886T AT01970886T ATE333888T1 AT E333888 T1 ATE333888 T1 AT E333888T1 AT 01970886 T AT01970886 T AT 01970886T AT 01970886 T AT01970886 T AT 01970886T AT E333888 T1 ATE333888 T1 AT E333888T1
- Authority
- AT
- Austria
- Prior art keywords
- inflammation
- treatment
- extracellular domain
- polypeptide containing
- seq
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 101001044895 Homo sapiens Interleukin-20 receptor subunit beta Proteins 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 title 1
- 102100022706 Interleukin-20 receptor subunit alpha Human genes 0.000 title 1
- 101710174006 Interleukin-20 receptor subunit alpha Proteins 0.000 title 1
- 102100022705 Interleukin-20 receptor subunit beta Human genes 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 4
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23330500P | 2000-09-15 | 2000-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE333888T1 true ATE333888T1 (de) | 2006-08-15 |
Family
ID=22876714
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01970886T ATE333888T1 (de) | 2000-09-15 | 2001-09-13 | Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen |
| AT05028379T ATE460429T1 (de) | 2000-09-15 | 2001-09-13 | Polypeptide enthaltend extrazellulären domäne von il-20ra und/oderr il-20rb |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05028379T ATE460429T1 (de) | 2000-09-15 | 2001-09-13 | Polypeptide enthaltend extrazellulären domäne von il-20ra und/oderr il-20rb |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7855269B2 (de) |
| EP (2) | EP1803733B1 (de) |
| JP (1) | JP4908723B2 (de) |
| AT (2) | ATE333888T1 (de) |
| AU (1) | AU2001290837A1 (de) |
| CA (1) | CA2422033A1 (de) |
| DE (2) | DE60141546D1 (de) |
| DK (1) | DK1351703T3 (de) |
| ES (1) | ES2267814T3 (de) |
| WO (1) | WO2002022153A2 (de) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965704A (en) * | 1997-08-05 | 1999-10-12 | Zymogenetics, Inc. | Class two cytokine receptor-11 |
| DE60123998T2 (de) * | 2000-08-08 | 2007-09-06 | Zymogenetics, Inc., Seattle | Lösliche zcyctor 11 cytokinrezeptoren |
| ATE333888T1 (de) * | 2000-09-15 | 2006-08-15 | Zymogenetics Inc | Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen |
| JP2007525438A (ja) * | 2003-03-24 | 2007-09-06 | ザイモジェネティクス， インコーポレイテッド | 抗ｉｌ−２２ｒａ抗体および結合パートナー、ならびに炎症における使用法 |
| US20040248097A1 (en) * | 2003-05-23 | 2004-12-09 | Ming-Shi Chang | Interleukin-20 variants and promoters |
| WO2005014028A1 (en) * | 2003-08-08 | 2005-02-17 | Novo Nordisk A/S | Interleukin-20 for treating and diagnosing conditions associated with neovascularisation |
| EP2478912B1 (de) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Konjugate von Auristatin mit gegen HER2- oder CD22-gerichtete Antikörper und deren therapeutische Verwendung |
| WO2005052001A2 (en) * | 2003-11-21 | 2005-06-09 | Zymogenetics, Inc. | Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation |
| NZ579482A (en) | 2004-06-01 | 2011-02-25 | Genentech Inc | Antibody drug conjugates and methods |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| AU2005299809B2 (en) * | 2004-10-22 | 2010-12-02 | Zymogenetics, Inc. | Anti-IL-22RA antibodies and binding partners and methods of using in inflammation |
| EP1856156A2 (de) * | 2005-02-08 | 2007-11-21 | ZymoGenetics, Inc. | Anti-il-20-, anti-il-22- und anti-il-22ra-antikörper und bindungspartner sowie verwendungsverfahren bei entzündungen |
| EP2035452B1 (de) | 2006-06-22 | 2012-04-25 | Novo Nordisk A/S | Lösliche heterodimere rezeptoren und ihre verwendung |
| JP2013504585A (ja) | 2009-09-09 | 2013-02-07 | セントローズ， エルエルシー | 細胞外標的化薬物複合体 |
| SI2528625T1 (sl) | 2010-04-15 | 2013-11-29 | Spirogen Sarl | Pirolobenzodiazepini in njihovi konjugati |
| CA2799540A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| US20120121615A1 (en) | 2010-11-17 | 2012-05-17 | Flygare John A | Alaninyl maytansinol antibody conjugates |
| US8679767B2 (en) | 2011-05-12 | 2014-03-25 | Genentech, Inc. | Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides |
| BR112014009050B1 (pt) | 2011-10-14 | 2022-06-21 | Medimmune Limited | Conjugado anticorpo-fármaco de pirrolbenzodiazepinas, composição farmacêutica que compreende o mesmo, bem como compostos de pirrolbenzodiazepinas |
| WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
| HRP20182129T1 (hr) | 2012-10-12 | 2019-02-08 | Adc Therapeutics Sa | Konjugati protutijelo - pirolobenzodiazepin |
| JP6392765B2 (ja) | 2012-10-12 | 2018-09-19 | エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ | ピロロベンゾジアゼピン−抗体結合体 |
| EP2906296B1 (de) | 2012-10-12 | 2018-03-21 | ADC Therapeutics SA | Pyrrolobenzodiazepin-antikörper-konjugate |
| MX338711B (es) | 2012-10-12 | 2016-04-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| RS57694B1 (sr) | 2012-10-12 | 2018-11-30 | Adc Therapeutics Sa | Pirolobenzodiazepin - anti-psma konjugati antitela |
| EP2906297B1 (de) | 2012-10-12 | 2017-12-06 | ADC Therapeutics SA | Pyrrolobenzodiazepin-antikörper-konjugate |
| ES2680153T3 (es) | 2012-10-12 | 2018-09-04 | Adc Therapeutics Sa | Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas |
| CN105189507A (zh) | 2012-12-21 | 2015-12-23 | 斯皮罗根有限公司 | 吡咯并苯并二氮杂卓及其结合物 |
| CN110627797A (zh) | 2012-12-21 | 2019-12-31 | 麦迪穆有限责任公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
| TWI680766B (zh) | 2013-03-13 | 2020-01-01 | 英商梅迪繆思有限公司 | 吡咯并苯并二氮呯及其共軛物 |
| AU2014229529B2 (en) | 2013-03-13 | 2018-02-15 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| MX362970B (es) | 2013-03-13 | 2019-02-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| BR112016002829A2 (pt) | 2013-08-12 | 2017-09-19 | Genentech Inc | Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| EP3054983B1 (de) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepin-antikörper-konjugate |
| WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| JP6671292B2 (ja) | 2013-12-16 | 2020-03-25 | ジェネンテック， インコーポレイテッド | ペプチド模倣化合物及びその抗体−薬物コンジュゲート |
| EP3082876B1 (de) | 2013-12-16 | 2018-01-17 | Genentech, Inc. | 1-(chlormethyl)-2,3-dihydro-1h-benzo[e]indoldimer-antikörper-wirkstoff-konjugatverbindungen und verfahren zur verwendung und behandlung |
| WO2015095227A2 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
| US10695406B2 (en) | 2014-05-27 | 2020-06-30 | The University Of Queensland | Modulation of cellular stress using a B-cell oxidative and/or endoplasmic reticulum stress inhibitor and a targeting agent |
| PE20170441A1 (es) | 2014-06-06 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos |
| EP3193940A1 (de) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepine und konjugate daraus |
| SG11201701128YA (en) | 2014-09-12 | 2017-03-30 | Genentech Inc | Cysteine engineered antibodies and conjugates |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| WO2016040825A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
| CN107073136A (zh) | 2014-09-17 | 2017-08-18 | 健泰科生物技术公司 | 吡咯并苯并二氮杂卓及其抗体二硫化物偶联物 |
| CN107148285B (zh) | 2014-11-25 | 2022-01-04 | Adc治疗股份有限公司 | 吡咯并苯并二氮杂䓬-抗体缀合物 |
| AU2015358532C1 (en) | 2014-12-03 | 2020-10-29 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| MX2017015260A (es) | 2015-06-03 | 2018-02-19 | Squibb Bristol Myers Co | Anticuerpos anti receptor de factor de necrosis tumoral inducible por glucocorticoide (gitr) para diagnostico del cancer. |
| CR20180243A (es) | 2015-10-02 | 2018-07-31 | Genentech Inc | Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso |
| MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
| EP3365025B1 (de) | 2015-10-20 | 2020-07-15 | Genentech, Inc. | Calicheamicin-antikörper-arzneimittelkonjugate und verfahren zur verwendung |
| AU2016356780A1 (en) | 2015-11-19 | 2018-06-28 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| CN108700598A (zh) | 2016-03-25 | 2018-10-23 | 豪夫迈·罗氏有限公司 | 多路总抗体和抗体缀合的药物量化测定法 |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| CN118436801A (zh) | 2016-05-20 | 2024-08-06 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| EP3465221B1 (de) | 2016-05-27 | 2020-07-22 | H. Hoffnabb-La Roche Ag | Bioanalytisches verfahren zur charakterisierung von ortsspezifischen antikörper-wirkstoff-konjugaten |
| WO2017214024A1 (en) | 2016-06-06 | 2017-12-14 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
| CN109689111B (zh) | 2016-08-11 | 2024-04-05 | 基因泰克公司 | 吡咯并苯并二氮杂䓬前药及其抗体缀合物 |
| JP7050770B2 (ja) | 2016-10-05 | 2022-04-08 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗体薬物コンジュゲートの調製方法 |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| RS61795B1 (sr) | 2017-02-08 | 2021-06-30 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin antitela |
| CN110582505B (zh) | 2017-04-18 | 2021-04-02 | 免疫医疗有限公司 | 吡咯并苯并二氮杂*缀合物 |
| WO2018193102A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| CN110869392A (zh) | 2017-05-16 | 2020-03-06 | 百时美施贵宝公司 | 用抗gitr激动性抗体治疗癌症 |
| CA3064804A1 (en) | 2017-06-14 | 2018-12-20 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-cd19 adc |
| KR102270107B1 (ko) | 2017-08-18 | 2021-06-30 | 메디뮨 리미티드 | 피롤로벤조디아제핀 컨쥬게이트 |
| EP3684773B1 (de) | 2017-09-20 | 2026-04-29 | pH Pharma Co., Ltd. | Thailanstatinanaloga |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
| JP7708662B2 (ja) | 2018-10-24 | 2025-07-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | コンジュゲート化された化学的分解誘導物質および使用方法 |
| JP2022513198A (ja) | 2018-12-10 | 2022-02-07 | ジェネンテック， インコーポレイテッド | Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
| CN113631560B (zh) | 2019-03-15 | 2025-02-18 | 麦迪穆有限责任公司 | 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物 |
| EP4426727A2 (de) | 2021-11-03 | 2024-09-11 | Hangzhou Dac Biotech Co., Ltd. | Spezifische konjugation eines antikörpers |
| WO2024138128A2 (en) | 2022-12-23 | 2024-06-27 | Genentech, Inc. | Cereblon degrader conjugates, and uses thereof |
| KR20260012304A (ko) | 2023-04-17 | 2026-01-26 | 피크 바이오, 인크. | 항체 및 항체-약물 접합체 및 사용 방법 및 합성 공정 및 중간체 |
| WO2026006688A2 (en) | 2024-06-28 | 2026-01-02 | Firefly Bio, Inc. | Degrader antibody conjugates and uses thereof |
| WO2026006689A2 (en) | 2024-06-28 | 2026-01-02 | Firefly Bio, Inc. | Bcl-xl degrader antibody conjugates and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567584A (en) * | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
| US5436155A (en) * | 1991-12-31 | 1995-07-25 | Arch Development Corporation | Isolated DNA encoding a somatostatin receptor |
| US5789192A (en) * | 1992-12-10 | 1998-08-04 | Schering Corporation | Mammalian receptors for interleukin-10 (IL-10) |
| US5985614A (en) * | 1996-08-30 | 1999-11-16 | Human Genome Sciences, Inc. | Polynucleotides encoding interleukin-19 |
| US5945511A (en) * | 1997-02-20 | 1999-08-31 | Zymogenetics, Inc. | Class II cytokine receptor |
| WO2000078961A1 (en) | 1999-06-23 | 2000-12-28 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| JP2001510035A (ja) | 1997-07-16 | 2001-07-31 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | インターロイキン−２０ |
| US6486301B1 (en) * | 1997-07-16 | 2002-11-26 | Human Genome Sciences, Inc. | Interleukin-20 |
| US5965704A (en) | 1997-08-05 | 1999-10-12 | Zymogenetics, Inc. | Class two cytokine receptor-11 |
| WO1999007740A2 (en) | 1997-08-06 | 1999-02-18 | Zymogenetics, Inc. | Lipocalin homologs |
| US6576743B1 (en) * | 1997-11-26 | 2003-06-10 | Zymogenetics, Inc. | Mammalian cytokine-like polypeptide-10 |
| IL136076A0 (en) | 1997-11-26 | 2001-05-20 | Zymogenetics Inc | Mammalian cytokin-like polypeptide -10 |
| EP1047781B1 (de) | 1998-01-23 | 2004-07-28 | Immunex Corporation | Rezeptoren für il-18 |
| WO1999046379A2 (en) | 1998-03-09 | 1999-09-16 | Schering Corporation | Human receptor proteins; related reagents and methods |
| ES2312205T3 (es) | 1998-03-10 | 2009-02-16 | Genentech, Inc. | Nuevo polipeptido y acidos nucleicos que lo codifican. |
| US6982320B2 (en) | 1998-03-19 | 2006-01-03 | Human Genome Sciences, Inc. | Cytokine receptor common gamma chain like |
| AU5203199A (en) | 1998-05-26 | 1999-12-13 | Procter & Gamble Company, The | Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system |
| NZ531664A (en) | 1998-09-01 | 2005-07-29 | Genentech Inc | Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family |
| EP1141008A1 (de) | 1998-12-31 | 2001-10-10 | Millennium Pharmaceuticals, Inc. | Cytokinin klasse ii rezeptor-ähnliche proteine und für diese kodierende nukleinsäuren |
| AU5047600A (en) | 1999-05-27 | 2000-12-18 | Schering Corporation | Mammalian interleukin-10 homologs: il-d110 and il-d210 |
| US6610286B2 (en) * | 1999-12-23 | 2003-08-26 | Zymogenetics, Inc. | Method for treating inflammation using soluble receptors to interleukin-20 |
| US7122632B2 (en) * | 1999-12-23 | 2006-10-17 | Zymogenetics, Inc. | Soluble Interleukin-20 receptor |
| AU783473B2 (en) | 1999-12-23 | 2005-10-27 | Zymogenetics Inc. | Soluble interleukin-20 receptor |
| EP1244708B8 (de) * | 1999-12-23 | 2007-03-07 | ZymoGenetics, Inc. | Verfahren zur behandlung von entzündungen |
| DE60123998T2 (de) | 2000-08-08 | 2007-09-06 | Zymogenetics, Inc., Seattle | Lösliche zcyctor 11 cytokinrezeptoren |
| ATE333888T1 (de) * | 2000-09-15 | 2006-08-15 | Zymogenetics Inc | Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen |
| EP1390060A2 (de) | 2001-01-26 | 2004-02-25 | Eli Lilly And Company | Verwendung von lp82 zur behandlung von störungen des körpergewichtes |
| CA2433933A1 (en) | 2001-02-28 | 2002-09-12 | Eli Lilly And Company | Use of lp82 to treat hematopoietic disorders |
| EP1399472B1 (de) | 2001-03-09 | 2009-06-03 | ZymoGenetics, Inc. | Löslicher heterodimerer cytokinrezeptor |
| DE10154579A1 (de) | 2001-11-07 | 2003-05-28 | Medigene Ag | Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen |
| CA2467723C (en) | 2001-12-17 | 2011-09-27 | Zymogenetics, Inc. | Method for treating cervical cancer |
| JP2007525438A (ja) | 2003-03-24 | 2007-09-06 | ザイモジェネティクス， インコーポレイテッド | 抗ｉｌ−２２ｒａ抗体および結合パートナー、ならびに炎症における使用法 |
-
2001
- 2001-09-13 AT AT01970886T patent/ATE333888T1/de active
- 2001-09-13 WO PCT/US2001/028557 patent/WO2002022153A2/en not_active Ceased
- 2001-09-13 DE DE60141546T patent/DE60141546D1/de not_active Expired - Lifetime
- 2001-09-13 ES ES01970886T patent/ES2267814T3/es not_active Expired - Lifetime
- 2001-09-13 EP EP05028379A patent/EP1803733B1/de not_active Expired - Lifetime
- 2001-09-13 AT AT05028379T patent/ATE460429T1/de not_active IP Right Cessation
- 2001-09-13 AU AU2001290837A patent/AU2001290837A1/en not_active Abandoned
- 2001-09-13 DE DE60121808T patent/DE60121808T2/de not_active Expired - Lifetime
- 2001-09-13 DK DK01970886T patent/DK1351703T3/da active
- 2001-09-13 US US09/951,268 patent/US7855269B2/en not_active Expired - Fee Related
- 2001-09-13 JP JP2002526403A patent/JP4908723B2/ja not_active Expired - Fee Related
- 2001-09-13 CA CA002422033A patent/CA2422033A1/en not_active Abandoned
- 2001-09-13 EP EP01970886A patent/EP1351703B1/de not_active Expired - Lifetime
-
2010
- 2010-11-09 US US12/942,302 patent/US20110077207A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1351703B1 (de) | 2006-07-26 |
| DE60121808T2 (de) | 2007-03-29 |
| US7855269B2 (en) | 2010-12-21 |
| US20110077207A1 (en) | 2011-03-31 |
| DE60141546D1 (de) | 2010-04-22 |
| JP2004525074A (ja) | 2004-08-19 |
| CA2422033A1 (en) | 2002-03-21 |
| WO2002022153A2 (en) | 2002-03-21 |
| AU2001290837A1 (en) | 2002-03-26 |
| ATE460429T1 (de) | 2010-03-15 |
| EP1351703A2 (de) | 2003-10-15 |
| WO2002022153A3 (en) | 2003-06-19 |
| EP1803733A2 (de) | 2007-07-04 |
| DK1351703T3 (da) | 2006-11-27 |
| ES2267814T3 (es) | 2007-03-16 |
| DE60121808D1 (de) | 2006-09-07 |
| EP1803733A3 (de) | 2007-10-31 |
| JP4908723B2 (ja) | 2012-04-04 |
| EP1803733B1 (de) | 2010-03-10 |
| US20020085992A1 (en) | 2002-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60121808D1 (de) | Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen | |
| IL189629A0 (en) | Compositions containing human ctla-4 antibodies | |
| ATE272650T1 (de) | Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes | |
| DE60023870D1 (de) | Verfahren zur herstellung von 3-aryloxy-3-arylpropylamine und deren zwischenprodukte | |
| ATE262895T1 (de) | Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis | |
| ATE224713T1 (de) | Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression | |
| DE60333963D1 (de) | Zytokin Ligand zur Behandlung von Asthma und Atemwegsüberreaktivität | |
| ATE462006T1 (de) | Isoform des vegfs | |
| ATE428413T1 (de) | Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen | |
| DE60331546D1 (de) | Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung | |
| DE60023860D1 (de) | Verfahren zur herstellung von rekombinanten peptiden | |
| PL322001A1 (en) | 1-aryl-2-acetylamino ethane compounds, their application as antagonists of neurokinin, in particular of neurokinin 1 | |
| DE69328549D1 (de) | Für einen humanen serotoninrezeptor (5-ht4b) kodierende dns und ihre verwendung | |
| DE69808475D1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
| DK0840792T3 (da) | (S)-hydroxynitrillyase fra Hevea brasiliensis | |
| ATE313561T1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
| DE60329115D1 (de) | Tumorantigenprotein und dessen verwendung | |
| ATE405577T1 (de) | Lactam dipeptid und dessen verwendung zur inhibierung der beta-amyloid peptid frisetzung | |
| DE60234843D1 (de) | Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten | |
| ATE244760T1 (de) | Wachtumsfaktor aus der harp-reihe, verfahren zu ihrer herstellung und verwendungen davon | |
| DE60321443D1 (de) | Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung | |
| ATE292970T1 (de) | Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden | |
| DE69519654D1 (de) | htFIIIA Gen | |
| EP1533378A3 (de) | tks7, ein tyrosinkinase-substrat-protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1351703 Country of ref document: EP |